Do analysts rate DRMA or DSY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dermata Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Big Tree Cloud 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, DRMA or DSY?

Dermata Therapeutics has higher earnings, but lower revenue than Big Tree Cloud. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dermata Therapeutics N/A N/A -$7.56M -$4.39 N/A Big Tree Cloud $2.56M 6.44 -$32.53M N/A N/A

Is DRMA or DSY more profitable?

Big Tree Cloud's return on equity of 0.00% beat Dermata Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dermata Therapeutics N/A -166.66% -130.13% Big Tree Cloud N/A N/A N/A

Do analysts recommend MTEX or DRMA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mannatech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dermata Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to MTEX or DRMA?

In the previous week, Mannatech had 1 more articles in the media than Dermata Therapeutics. MarketBeat recorded 3 mentions for Mannatech and 2 mentions for Dermata Therapeutics. Mannatech's average media sentiment score of 0.54 beat Dermata Therapeutics' score of 0.00 indicating that Mannatech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mannatech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dermata Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend DRMA or NAII?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dermata Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Natural Alternatives International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend DRMA or NHTC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dermata Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Natural Health Trends 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to DRMA or NHTC?

In the previous week, Natural Health Trends had 1 more articles in the media than Dermata Therapeutics. MarketBeat recorded 3 mentions for Natural Health Trends and 2 mentions for Dermata Therapeutics. Natural Health Trends' average media sentiment score of 0.75 beat Dermata Therapeutics' score of 0.00 indicating that Natural Health Trends is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dermata Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Natural Health Trends 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate DRMA or ATPC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dermata Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Agape ATP 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Dermata Therapeutics (DRMA) Competitors

$1.02 -0.05 (-4.67%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.07 +0.05 (+4.90%)

As of 10/9/2026 07:21 PM Eastern

Compare

DRMA vs. DSY, MTEX, NAII, NHTC, and ATPC

Should you buy Dermata Therapeutics stock or one of its competitors? Dermata Therapeutics's main competitors and comparable companies include Big Tree Cloud (DSY), Mannatech (MTEX), Natural Alternatives International (NAII), Natural Health Trends (NHTC), and Agape ATP (ATPC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "personal care products" industry.

How does Dermata Therapeutics compare to Big Tree Cloud?

Dermata Therapeutics (NASDAQ:DRMA) and Big Tree Cloud (NASDAQ:DSY) are both small-cap consumer staples companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

Big Tree Cloud's return on equity of 0.00% beat Dermata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dermata Therapeutics	N/A	-166.66%	-130.13%
Big Tree Cloud	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Big Tree Cloud	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Dermata Therapeutics had 1 more articles in the media than Big Tree Cloud. MarketBeat recorded 2 mentions for Dermata Therapeutics and 1 mentions for Big Tree Cloud. Dermata Therapeutics' average media sentiment score of 0.00 equaled Big Tree Cloud'saverage media sentiment score.

Company	Overall Sentiment
Dermata Therapeutics	Neutral
Big Tree Cloud	Neutral

Dermata Therapeutics has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, Big Tree Cloud has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market.

8.7% of Dermata Therapeutics shares are held by institutional investors. Comparatively, 60.2% of Big Tree Cloud shares are held by institutional investors. 21.9% of Dermata Therapeutics shares are held by insiders. Comparatively, 34.1% of Big Tree Cloud shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Dermata Therapeutics has higher earnings, but lower revenue than Big Tree Cloud.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dermata Therapeutics	N/A	N/A	-$7.56M	-$4.39	N/A
Big Tree Cloud	$2.56M	6.44	-$32.53M	N/A	N/A

Summary

Big Tree Cloud beats Dermata Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Dermata Therapeutics compare to Mannatech?

Mannatech (NASDAQ:MTEX) and Dermata Therapeutics (NASDAQ:DRMA) are both small-cap consumer staples companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

Dermata Therapeutics has a net margin of 0.00% compared to Mannatech's net margin of -6.90%. Dermata Therapeutics' return on equity of -166.66% beat Mannatech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mannatech	-6.90%	-2,383.34%	-24.43%
Dermata Therapeutics	N/A	-166.66%	-130.13%

In the previous week, Mannatech had 1 more articles in the media than Dermata Therapeutics. MarketBeat recorded 3 mentions for Mannatech and 2 mentions for Dermata Therapeutics. Mannatech's average media sentiment score of 0.54 beat Dermata Therapeutics' score of 0.00 indicating that Mannatech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mannatech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dermata Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

13.0% of Mannatech shares are held by institutional investors. Comparatively, 8.7% of Dermata Therapeutics shares are held by institutional investors. 47.5% of Mannatech shares are held by company insiders. Comparatively, 21.9% of Dermata Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Dermata Therapeutics has lower revenue, but higher earnings than Mannatech. Mannatech is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mannatech	$108.04M	0.14	-$15.21M	-$3.91	N/A
Dermata Therapeutics	N/A	N/A	-$7.56M	-$4.39	N/A

Mannatech has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, Dermata Therapeutics has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mannatech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Mannatech beats Dermata Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Dermata Therapeutics compare to Natural Alternatives International?

Dermata Therapeutics (NASDAQ:DRMA) and Natural Alternatives International (NASDAQ:NAII) are both small-cap consumer staples companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Natural Alternatives International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Dermata Therapeutics has higher earnings, but lower revenue than Natural Alternatives International. Natural Alternatives International is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dermata Therapeutics	N/A	N/A	-$7.56M	-$4.39	N/A
Natural Alternatives International	$142.51M	0.05	-$20.69M	-$3.42	N/A

8.7% of Dermata Therapeutics shares are held by institutional investors. Comparatively, 32.4% of Natural Alternatives International shares are held by institutional investors. 21.9% of Dermata Therapeutics shares are held by insiders. Comparatively, 20.8% of Natural Alternatives International shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Dermata Therapeutics has a net margin of 0.00% compared to Natural Alternatives International's net margin of -14.52%. Natural Alternatives International's return on equity of -16.51% beat Dermata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dermata Therapeutics	N/A	-166.66%	-130.13%
Natural Alternatives International	-14.52%	-16.51%	-6.95%

Dermata Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market. Comparatively, Natural Alternatives International has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market.

In the previous week, Natural Alternatives International had 1 more articles in the media than Dermata Therapeutics. MarketBeat recorded 3 mentions for Natural Alternatives International and 2 mentions for Dermata Therapeutics. Natural Alternatives International's average media sentiment score of 0.65 beat Dermata Therapeutics' score of 0.00 indicating that Natural Alternatives International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dermata Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Natural Alternatives International	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Natural Alternatives International beats Dermata Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Dermata Therapeutics compare to Natural Health Trends?

Dermata Therapeutics (NASDAQ:DRMA) and Natural Health Trends (NASDAQ:NHTC) are both small-cap consumer staples companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Natural Health Trends has higher revenue and earnings than Dermata Therapeutics. Natural Health Trends is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dermata Therapeutics	N/A	N/A	-$7.56M	-$4.39	N/A
Natural Health Trends	$39.78M	0.20	-$880K	-$0.16	N/A

Dermata Therapeutics has a net margin of 0.00% compared to Natural Health Trends' net margin of -4.51%. Natural Health Trends' return on equity of -8.00% beat Dermata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dermata Therapeutics	N/A	-166.66%	-130.13%
Natural Health Trends	-4.51%	-8.00%	-4.58%

In the previous week, Natural Health Trends had 1 more articles in the media than Dermata Therapeutics. MarketBeat recorded 3 mentions for Natural Health Trends and 2 mentions for Dermata Therapeutics. Natural Health Trends' average media sentiment score of 0.75 beat Dermata Therapeutics' score of 0.00 indicating that Natural Health Trends is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dermata Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Natural Health Trends	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dermata Therapeutics has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market. Comparatively, Natural Health Trends has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

8.7% of Dermata Therapeutics shares are owned by institutional investors. Comparatively, 10.1% of Natural Health Trends shares are owned by institutional investors. 21.9% of Dermata Therapeutics shares are owned by insiders. Comparatively, 12.9% of Natural Health Trends shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Natural Health Trends	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Natural Health Trends beats Dermata Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Dermata Therapeutics compare to Agape ATP?

Dermata Therapeutics (NASDAQ:DRMA) and Agape ATP (NASDAQ:ATPC) are both small-cap consumer staples companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Agape ATP	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Dermata Therapeutics has a net margin of 0.00% compared to Agape ATP's net margin of -85.94%. Agape ATP's return on equity of -5.47% beat Dermata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dermata Therapeutics	N/A	-166.66%	-130.13%
Agape ATP	-85.94%	-5.47%	-4.94%

In the previous week, Dermata Therapeutics and Dermata Therapeutics both had 2 articles in the media. Dermata Therapeutics' average media sentiment score of 0.00 equaled Agape ATP'saverage media sentiment score.

Company	Overall Sentiment
Dermata Therapeutics	Neutral
Agape ATP	Neutral

8.7% of Dermata Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of Agape ATP shares are owned by institutional investors. 21.9% of Dermata Therapeutics shares are owned by insiders. Comparatively, 2.0% of Agape ATP shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Agape ATP has higher revenue and earnings than Dermata Therapeutics. Agape ATP is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dermata Therapeutics	N/A	N/A	-$7.56M	-$4.39	N/A
Agape ATP	$1.32M	1.69	-$2.28M	-$0.74	N/A

Dermata Therapeutics has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, Agape ATP has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market.

Summary

Dermata Therapeutics and Agape ATP tied by winning 5 of the 10 factors compared between the two stocks.

Get Dermata Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DRMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DRMA vs. The Competition

Export

Metric	Dermata Therapeutics	Personal Care Products Industry	Consumer Staples Sector	NASDAQ Exchange
Market Cap	$4.30M	$23.02B	$15.87B	$13.21B
Dividend Yield	N/A	5.54%	3.32%	16.37%
P/E Ratio	-0.23	21.85	13.88	26.16
Price / Sales	N/A	12.84	265,659.24	107.42
Price / Cash	N/A	26.14	57.04	53.09
Price / Book	0.47	2.89	4.34	6.34
Net Income	-$7.56M	$1.13B	$844.17M	$381.90M
7 Day Performance	-7.69%	1.21%	0.84%	-1.41%
1 Month Performance	-15.00%	-4.23%	-2.54%	-3.48%
1 Year Performance	-75.42%	-19.53%	9.73%	1.16%

Dermata Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DRMA Dermata Therapeutics	0.7085 of 5 stars	$1.02 -4.7%	N/A	-77.5%	$4.30M	N/A	N/A	9
DSY Big Tree Cloud	0.4989 of 5 stars	$3.71 +3.2%	N/A	-80.3%	$17.61M	$2.02M	N/A	20	Gap Down
MTEX Mannatech	0.6846 of 5 stars	$7.40 -2.6%	N/A	-8.3%	$14.28M	$107.36M	N/A	170	Gap Down
NAII Natural Alternatives International	1.3129 of 5 stars	$1.46 -0.7%	N/A	-59.9%	$9.17M	$142.51M	N/A	234	Short Interest Decrease Gap Up
NHTC Natural Health Trends	1.7074 of 5 stars	$1.04 +0.9%	N/A	-78.7%	$8.91M	$36.04M	N/A	120	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DRMA) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dermata Therapeutics (DRMA) Competitors

DRMA vs. DSY, MTEX, NAII, NHTC, and ATPC

How does Dermata Therapeutics compare to Big Tree Cloud?

Summary

How does Dermata Therapeutics compare to Mannatech?

Summary

How does Dermata Therapeutics compare to Natural Alternatives International?

Summary

How does Dermata Therapeutics compare to Natural Health Trends?

Summary

How does Dermata Therapeutics compare to Agape ATP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRMA vs. The Competition

Dermata Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dermata Therapeutics (DRMA) Competitors

DRMA vs. DSY, MTEX, NAII, NHTC, and ATPC

How does Dermata Therapeutics compare to Big Tree Cloud?

Is DRMA or DSY more profitable?

Do analysts rate DRMA or DSY?

Does the media prefer DRMA or DSY?

Which has more volatility & risk, DRMA or DSY?

Do institutionals & insiders believe in DRMA or DSY?

Which has stronger valuation and earnings, DRMA or DSY?

Summary

How does Dermata Therapeutics compare to Mannatech?

Is MTEX or DRMA more profitable?

Does the media refer more to MTEX or DRMA?

Do institutionals and insiders have more ownership in MTEX or DRMA?

Which has stronger earnings and valuation, MTEX or DRMA?

Which has more volatility and risk, MTEX or DRMA?

Do analysts recommend MTEX or DRMA?

Summary

How does Dermata Therapeutics compare to Natural Alternatives International?

Do analysts recommend DRMA or NAII?

Which has stronger earnings and valuation, DRMA or NAII?

Do institutionals & insiders believe in DRMA or NAII?

Is DRMA or NAII more profitable?

Which has more volatility & risk, DRMA or NAII?

Does the media prefer DRMA or NAII?

Summary

How does Dermata Therapeutics compare to Natural Health Trends?

Which has preferable valuation and earnings, DRMA or NHTC?

Is DRMA or NHTC more profitable?

Does the media refer more to DRMA or NHTC?

Which has more volatility and risk, DRMA or NHTC?

Do institutionals and insiders hold more shares of DRMA or NHTC?

Do analysts recommend DRMA or NHTC?

Summary

How does Dermata Therapeutics compare to Agape ATP?

Do analysts rate DRMA or ATPC?

Is DRMA or ATPC more profitable?

Does the media refer more to DRMA or ATPC?

Do insiders & institutionals believe in DRMA or ATPC?

Which has stronger earnings & valuation, DRMA or ATPC?

Which has more volatility and risk, DRMA or ATPC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRMA vs. The Competition

Dermata Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools